Cagrilintide 5mg + Semaglutide 5mg combination lyophilized powder 10mg/bottle - Core Introduction
Research-grade dual-target synergistic peptide | Made in China, long-acting AMYR/GLP-1R dual agonist combination 10mg/vial
Combination ingredients : Cagrilintide 5mg (long-acting amylin analog) + Semaglutide 5mg (long-acting GLP-1 analog)
Combination ratio : 1:1 mass ratio
Purity : The purity of each component is ≥99.0% (RP-HPLC detection).
Total peptide content : ≥95.0% (amino acid analysis)
Appearance : White or off-white lyophilized powder
Storage : Store frozen at -20℃ away from light. After thawing, refrigerate at 2-8℃. Avoid repeated freeze-thaw cycles.
Core advantages and functions
This product is a precisely 1:1 mass ratio lyophilized powder combining the amylintide receptor (AMYR) agonist Cagrilintide and the glucagon-like peptide-1 receptor (GLP-1R) agonist Semaglutide , representing the highest level of strategy in current research on combination therapies for metabolic diseases . Through a dual, complementary, and synergistic mechanism of action -simultaneously targeting central appetite regulation and energy expenditure, delaying gastric emptying, and enhancing insulin sensitivity-it has demonstrated breakthrough weight loss and metabolic improvement effects beyond monotherapy in preclinical studies of obesity, type 2 diabetes, and related metabolic complications . It is a key research tool for achieving the goal of "synergistic efficacy and reduced side effects . "
✅ Synergistic mechanism :
The "two-circuit" inhibition of central appetite :
Semaglutide (GLP-1R pathway) : Acts on arcuate nucleus POMC neurons and paraventricular nucleus of the hypothalamus to produce long-lasting satiety signals and reduce hunger.
Cagrilintide (amylinin pathway) : Acts on brain regions such as the parabrachial nucleus and amygdala , particularly regulating the nausea and aversion-related centers , further strengthening feeding inhibition, and may also regulate the hedonic value of food.
Multi-target optimization of peripheral metabolism :
Synergistic delay of gastric emptying : Both significantly delay gastric emptying, and their additive effect prolongs satiety and reduces postprandial blood glucose fluctuations.
Synergistic regulation of energy expenditure : Cagrilintide can slightly increase energy expenditure, complementing the weight management effect of semaglutide.
Improve insulin sensitivity : Through weight loss and direct action, it synergistically improves the response of peripheral tissues to insulin.
Clinical advantages :
Stronger weight loss effect : Preclinical and early clinical data show a weight loss effect of 1+1>2.
Superior metabolic improvement : While reducing weight, it also provides more comprehensive improvement in cardiovascular metabolic indicators such as blood sugar, blood lipids, and blood pressure.
Potential tolerability optimization : Through mechanistic complementarity, it may be possible to use relatively low doses of monotherapy, thereby reducing the gastrointestinal side effects that may result from high doses of monotherapy.
✅Quality advantages of Chinese manufacturers :
High purity of components guaranteed :
Cagrilintide : Utilizing site-directed fatty acid chain modification technology , its purity is ≥99.0%, ensuring long-lasting AMYR agonist activity.
Semaglutide : Utilizing optimized fermentation and purification processes , it achieves a purity of ≥99.0% and exhibits consistent fatty acid side chain modifications and spatial structures with the original drug .
Precise formulation and co-freeze-drying process :
High-precision micro-weighing and mixing technology is used to ensure the accuracy of the 1:1 mass ratio, with batch-to-batch variation of <±2%.
By employing advanced co-freeze-drying formulations and processes , the stability, compatibility, and uniformity of the two peptides during freeze-drying and reconstitution are ensured , preventing aggregation or degradation caused by interactions.
Strict quality control throughout the entire process :
Identification : The two components were confirmed by HPLC peptide chromatogram and mass spectrometry, respectively.
Content : The contents of Cagrilintide and Semaglutide were determined by specific HPLC method, and each was controlled to be 90.0%-110.0% of the labeled amount.
Related substances : control single impurities ≤0.5%, total impurities ≤2.0%.
Activity validation : Cell-based cAMP function experiments were performed to validate the agonistic activity against AMYR and GLP-1R (EC50 values met the standards).
Safety indicators : bacterial endotoxin <10 EU/mg, sterility test meets the requirements.
Complete comparability study : Provides key quality attributes (CQA) comparison data of the two components with their respective original/reference products , including primary structure, higher structure, purity profile, activity, etc., to demonstrate their consistency.
✅Product Features :
Precise formulation : Optimized 1:1 fixed-dose combination provides a standardized tool for synergistic effect studies.
Synergistic and efficient : Preclinical data confirms that the combined use of drugs has a significantly better weight loss effect than the individual components used alone.
Complementary mechanisms : covering different neural circuits and peripheral targets related to food intake control and energy balance.
The gold standard for research : providing reliable, high-quality raw materials for evaluating the "Cagri+Sema" combined strategy.
Usage and Storage Guide
1. Reconstitution and preparation :
Special solvent :
The accompanying special reconstitution diluent (usually water for injection containing specific buffers and stabilizers, pH approximately 8.0-8.5) must be used to ensure the stability of both peptides simultaneously.
The use of ordinary physiological saline, sterile water for injection, or buffer solutions with mismatched pH is strictly prohibited .
Standard preparation procedure :
Slowly inject 1.0 mL of the special diluent along the inner wall of the vial.
Gently rotate the vial horizontally in the palm of your hand for at least 2-3 minutes until the freeze-dried cake is completely dissolved, forming a clear, colorless isotonic solution. Avoid vigorous shaking, agitation, or vortexing .
A mixed stock solution of Cagrilintide 5 mg/mL + Semaglutide 5 mg/mL was obtained (total concentration 10 mg/mL).
If injection is required, it can be further diluted with a special diluent or physiological saline containing 0.1% human serum albumin and then gently mixed.
Key points to note :
Reconstitution is recommended to be performed at room temperature.
The reconstituted solution should be used within 1 hour to prevent degradation or aggregation.
Before administering the medication, be sure to visually inspect the solution. It should be clear, colorless, and free of visible particles .
This product is a fixed-dose compound ; do not attempt to separate the two components or adjust their ratio.
2. Storage conditions :
Unreconstituted lyophilized powder :
Store frozen at -20℃ ± 5℃ , protected from light in the original packaging.
Under these conditions, the validity period is tentatively set at 24 months .
For long-term storage, it is recommended to store at -80℃ .
Repeated freezing and thawing is strictly prohibited .
Reconstituted solution :
If not used immediately, it can be refrigerated at 2-8℃ for no more than 24 hours .
It is not recommended to freeze reconstituted medication.
Transportation conditions :
It must be transported using dry ice (-78℃) throughout the entire process .
A temperature recorder should be included in the packaging.
3. Research and application plan :
Preclinical animal models :
Core model :
Diet-induced obesity (DIO) mice/rats : assessing synergistic weight loss, changes in body composition, food intake, and energy expenditure.
Zucker diabetic obese (ZDF) rats or ob/ob, db/db mice : to evaluate the synergistic effect on improving blood glucose, insulin sensitivity, and pancreatic function.
A high-fat, high-fructose diet-induced nonalcoholic steatohepatitis (NASH) model : evaluating the combined efficacy against hepatic steatosis, inflammation, and fibrosis.
Dosage regimen :
Recommended route : subcutaneous injection .
Dosage reference (based on total peptide mass, requires preliminary experimental optimization):
Low-dose group: 0.1 - 0.3 mg/kg
Medium dose group: 0.3 - 1.0 mg/kg
High-dose group: 1.0 - 3.0 mg/kg
Dosing frequency : Since both are long-acting formulations, they can be designed to be administered once a week .
Treatment course and monitoring :
Short-term efficacy: 4-8 weeks.
Long-term efficacy and mechanism: 12-24 weeks.
Monitoring indicators: weight, food intake, body composition (DXA or MRI), fasting blood glucose, oral glucose tolerance test (OGTT), insulin tolerance test (ITT), blood lipids, liver enzymes, intrahepatic lipid content, histopathology, and energy metabolism (indirect calorimetry).
Mechanism of action study :
Central mechanisms : Using techniques such as microinjection into brain regions, c-Fos immunohistochemistry, chemogenetics/optogenetics, etc., we analyzed the activation patterns and synergistic sites of the two on different feeding-related neural circuits.
Peripheral mechanisms : The hyperinsulin-orthoglucose clamp test was performed to assess systemic and tissue-specific insulin sensitivity; the effects on gastric emptying and gastrointestinal hormone secretion were investigated.
Safety assessment : Monitor gastrointestinal side effects (such as the rate of weight loss due to food intake suppression), heart rate, blood pressure, etc.
4. Experimental Design Suggestions :
Control group setup (crucial):
Solvent control group
Cagrilintide monotherapy group (equimolar dose)
Semaglutide monotherapy group (equimolar dose)
This compound group
(Optional) Other positive control drug groups
Dosage design : It is recommended to conduct a complete dose-response study and assess the synergistic index.
Why choose the Chinese-made Cagrilintide + Semaglutide combination?
A leader in compound technology : We have overcome the challenges of precise proportioning, compatibility, and co-freeze-drying of two long-acting peptides with different structures and modifications , ensuring the uniformity, stability, and activity of compound products .
Quality originates from design : control from the source of raw materials, conduct in-depth characterization of the two components, and carry out comprehensive quality research on the compound product to ensure that the synergistic effect of 1+1 > 2 can be reliably studied.
Strong supply chain and customization capabilities : We can reliably supply high-quality raw materials and provide customized compound products with different proportions according to specific research needs.
Excellent cost-effectiveness : Compared to purchasing two components separately and mixing them yourself, this compound product saves costs and time, and eliminates the proportioning errors, compatibility risks, and operational errors that may result from self-mixing . It is the first choice for those who pursue high-efficiency and high-quality research.
Research and application directions
Mechanism of synergistic treatment for metabolic diseases :
The cross-communication and integration mechanism of amylin and GLP-1 signaling pathways in the feeding centers such as the hypothalamus and brainstem.
The synergistic effect of combined drug therapy in reducing fat accumulation and improving liver fat metabolism.
Synergistic improvement effect and mechanism on cardiovascular metabolic risk factors.
New therapy development and optimization :
This provides a mechanistic reference and efficacy benchmark for the development of dual-target single-molecule drugs such as AMG 133.
To explore the optimal dosage, frequency, and duration of treatment, providing a basis for clinical protocol design.
To evaluate its therapeutic potential in specific populations, such as obese patients with NASH.
Translational medicine and biomarkers :
To identify biomarkers that can predict the response to the "Cagri+Sema" combination therapy.
To explore the effects of long-term treatment on metabolic memory and tissue remodeling.
Preclinical research data reference
Synergistic weight loss : In the DIO model, the weight loss effect of combined medication is significantly better than the sum of the effects of each component used alone, showing a clear synergistic effect .
Comprehensive metabolic benefits : The combination therapy group often showed better and more comprehensive improvements in improving insulin resistance, reducing liver fat content, and regulating blood lipids.
Tolerability : Preclinical studies suggest that, when achieving equivalent or better efficacy, combination therapy may have better tolerability due to the relatively lower dosage of each component .
Summarize
a prime example of the "synergistic therapy" concept in the field of metabolic disease drug development . This product combines two clinically validated, high-potency molecules with different mechanisms of action, providing an irreplaceable standardized research tool for exploring more potent, safer, and more comprehensive treatment options for metabolic diseases . Choosing this product means choosing an efficient, reliable, and cutting-edge research path , helping you achieve a leading position in the highly competitive field of metabolic research.
Need anything, please contact us
|
|
+852 4671 8216 |
|
Telegram |
Allenraws |
|
|
Allenraws810@gmail.com |
Hot Tags: cagrilintide 5mg+semaglutide 5mg 10mg/vial weight management and metabolic health, China cagrilintide 5mg+semaglutide 5mg 10mg/vial weight management and metabolic health manufacturers, suppliers, factory, AOD9604 Ideal For Competition Prep Peak Weeks, ace 031 1mg, buy aod 9604 pills, peptide cjc ipamorelin, Alternative to GHRP 6, hgh ipamorelin
